This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript

Cadence Pharmaceuticals Inc. (CADX)

Q3 2010 Earnings Call

November 5, 2010 8:30 AM ET

Executives

Ted Schroeder – President and CEO

Jim Breitmeyer – Executive Vice President and CMF

Scott Byrd – Senior Vice President and CCO

Bill LaRue – Senior Vice President and CFO.

Analysts

Charles Duncan – JMP Securities

Eric Schmidt – Cowen and Company

Adam Cutler – Canaccord Genuity

Joseph Schwartz – Leerink Swann

Irina Rivkind – Duncan Williams

Richard Lau – Wedbush Securities

Presentation

Operator

Good morning. And welcome to the Cadence Pharmaceuticals Third Quarter 2010 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO; Jim Breitmeyer, Executive Vice President and Chief Medical Officer; Scott Byrd, Senior Vice President and Chief Commercial Officer; and Bill LaRue, Senior Vice President and Chief Financial Officer.

At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company we will open the conference for question-and-answer after the management presentation. (Operator Instructions)

Our first speaker is Bill LaRue. Please go ahead, sir.

Bill LaRue

Thank you. Good morning, everyone. Before we get started today, I’d like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward-looking statements include statements regarding our readiness for and anticipated timing for the planned commercial launch of OFIRMEV, OFIRMEV’s market potential and ability to fulfill unmet medical needs, our beliefs that pharmacoeconomic issues will not be a significant barrier to formulary approvals, the sufficiency of our company’s capital resources to fund our operations through the launch of OFIRMEV and our financial estimates or projections.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs